AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22585541
Drug: pouched snus
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pouched snus (14.7 mg nicotine)
Trial: 22585541
Drug: loose snus
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loose snus (10.8 mg nicotine)
Trial: 22585541
Drug: nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nicotine gum (4.2 mg nicotine)
Trial: 22585541
Drug: pouched snus
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pouched snus (1 g portion, ~11 mg nicotine)
Trial: 21577030
Drug: 10-week twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-week twice weekly exercise group program (gymnastics, movement games, relaxation, walking, jogging)
Trial: 8904260
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diazepam and propofol
Trial: 2276106
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone call intervention in addition to usual care
Trial: 533286
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical applications of a steroid and nonsteroid anti-inflammatory agent
Trial: 533286
Drug: Nonsteroid anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroid anti-inflammatory agent
Trial: 533286
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of steroid and nonsteroid agents
Trial: 533286
Drug: Steroid or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid or nonsteroid agent alone
Trial: 533286
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of agents
Trial: 19088698
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.25 microg kg(‐1) hr(‐1))
Trial: 19088698
Drug: Midazolam infusion
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam infusion (25 microg kg(‐1) hr(‐1))
Trial: 17604045
Drug: Selective invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective invasive (SI) treatment strategy
Trial: 15998467
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (24 hours bed rest and ample fluid intake)
Trial: 7630912
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care regime using saline rinses
Trial: 7630912
Drug: Oral assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral assessment guide and protocol
Trial: 2905069
Drug: Temazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (10 mg for one night)
Trial: 20386078
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 2 weeks
Trial: 18377693
Drug: Co-enzyme Q10
RxNorm normalized name: Thrifty White Co-Enzyme Q10 100mg Capsule
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-enzyme Q10 (100 mg), Riboflavin (10 mg), Niacin (50 mg) along with Tamoxifen (10 mg twice per day)
Trial: 20356911
Drug: Intravenous n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous n-3 polyunsaturated fatty acids (PUFA) infusion (3.9 g)
Trial: 20356911
Drug: Intravenous n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous n-3 PUFA infusion
Trial: 11403364
Drug: Amlodipine (5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5/10 mg) +/‐ Perindopril (4/8 mg)
Trial: 11403364
Drug: Atenolol (50/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50/100 mg) +/‐ Bendroflumethiazide (1.25/2.5 mg) + K+
Trial: 9755995
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg at bedtime (maintenance group)
Trial: 9755995
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active therapy (antibiotic group)
Trial: 9755995
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg at bedtime (intent to treat analysis)
Trial: 9755995
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active therapy (intent to treat analysis)
Trial: 3283093
Drug: Amoxycillin sachets
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin sachets 3g twice daily for three days
Trial: 3283093
Drug: Amoxycillin capsules
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin capsules 500 mg three times daily for seven days
Trial: 3283093
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course high dose therapy
Trial: 29696564
Drug: M2000 (β-D-mannuronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2000 (β-D-mannuronic acid) administered at a dose of two capsules (500 mg) per day orally for 12 weeks
Trial: 23200102
Drug: GNbAC1 0.0025,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNbAC1 0.0025, 0.025, 0.15, 0.6, 2, or 6 mg/kg
Trial: 23200102
Drug: GNbAC1 2
RxNorm normalized name: Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNbAC1 2 and 6 mg/kg
Trial: 17957907
Drug: Ginger (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (0.5 gm capsule, twice daily)
Trial: 17957907
Drug: Dimenhydrinate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate (50 mg capsule, twice daily)
Trial: 11468200
Drug: Eptifibatide (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (180 microgram/kg bolus and 2.0 microgram/kg per minute infusion for 72 hours)
Trial: 21903957
Drug: Isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone soy protein (ISP) supplementation (25 g daily for 2.7 years)
Trial: 21903957
Drug: Isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone soy protein (ISP) supplementation (25 g daily for 2.7 years) in women <5 years postmenopausal
Trial: 19086328
Drug: Panitumumab monotherapy
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab monotherapy
Trial: 10450292
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet (rich in fruits, vegetables, and low-fat dairy products)
Trial: 10450292
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet (in participants with hypertension)
Trial: 10450292
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet (in participants without hypertension)
Trial: 8738446
Drug: Forceful epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forceful epidural corticosteroid injections (125 mg prednisolone acetate + 40 ml saline)
Trial: 8738446
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (125 mg prednisolone acetate alone)
Trial: 8738446
Drug: Forceful epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forceful epidural corticosteroid injections
Trial: 2018658
Drug: STH +
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: STH + CP (creatine phosphate 10.0 mmol/l)
Trial: 31607387
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (loading dose of 500 mg and continuous infusion of 250 mg h‐1)
Trial: 25365652
Drug: Sandwich Bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich Bone Augmentation (SBA)
Trial: 24707200
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of DTM and NSAID
Trial: 22960162
Drug: Motivational coaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational coaching at home and by phone with a health educator, mailed educational materials, and weekly text messages for 6 months.
Trial: 20071900
Drug: Koryo Hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Koryo Hand Therapy (KHT), applied three times a week for 8 weeks
Trial: 17395516
Drug: Weekly medical
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly medical support through SMS based upon weekly review of glucose values
Trial: 17395516
Drug: No SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No SMS (self‐monitored blood glucose values downloaded weekly without SMS)
Trial: 10102965
Drug: 7-day therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day therapy with ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d.
Trial: 10102965
Drug: 10-day therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day therapy with ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d.
Trial: 2185825
Drug: Maize starch
RxNorm normalized name: Maize starch
DrugBank: Starch, corn (DB11599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize starch paste with 240 g amylose/kg (S24)
Trial: 2185825
Drug: Maize starch
RxNorm normalized name: Maize starch
DrugBank: Starch, corn (DB11599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize starch paste with 500 g amylose/kg (S50)
Trial: 6109469
Drug: Midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.15 mg/kg body weight) injected over 60 seconds
Trial: 6109469
Drug: Midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.15 mg/kg body weight) injected over 15 seconds
Trial: 29029135
Drug: Simeprevir 150mg
RxNorm normalized name: SIMEPREVIR 150MG CAP
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 150mg once daily for 7 days
Trial: 29029135
Drug: Dolutegravir 50mg
RxNorm normalized name: DOLUTEGRAVIR 50MG TAB
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir 50mg once daily for 7 days
Trial: 29029135
Drug: Simeprevir 150mg
RxNorm normalized name: SIMEPREVIR 150MG CAP
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 150mg once daily plus Dolutegravir 50mg once daily for 7 days
Trial: 22708417
Drug: Physical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical training (PT) combined with standard pharmacotherapy and respiratory training
Trial: 15974417
Drug: Topical morphine
RxNorm normalized name: morphine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical morphine (10 mg morphine hydrochloride with Intrasite Gel)
Trial: 15974417
Drug: Placebo (Intrasite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Intrasite Gel with placebo)
Trial: 12902209
Drug: Three drugs
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three drugs FDC
Trial: 12902209
Drug: Four drugs
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four drugs FDC
Trial: 6094443
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g im or iv on call to the operating room)
Trial: 6094443
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g im or iv on call to the operating room, followed by 2 g intravenously at 6 hourly intervals for up to 24 h)
Trial: 2948731
Drug: 5 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/m2 5'‐dFUrd
Trial: 2948731
Drug: 3 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/m2 5'‐dFUrd
Trial: 29733038
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (control group).
Trial: 27718781
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg per day, 4-weeks-on, 2-weeks-off for 1 year)
Trial: 18551108
Drug: Daily exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exercise (EX)
Trial: 14556925
Drug: Glufosfamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glufosfamide (5 g/m²) administered via 1-hour intravenous infusion every 3 weeks
Trial: 10759342
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus Pindolol (FLX + PIN)
Trial: 10759342
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus Placebo (FLX + PLA)
Trial: 8636433
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no IL-2 therapy)
Trial: 6731261
Drug: Trimazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin (2 mg/kg)
Trial: 17685870
Drug: Local therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapies (anti-vascular endothelial growth factor strategies, anti-inflammatory agents, gene therapy, and stem cell therapy)
Trial: 17685870
Drug: Systemic drug
RxNorm normalized name: OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic drug administration (protein kinase C inhibitors and somatostatin analogs)
Trial: 17685870
Drug: Intravitreal delivery
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal delivery of local therapies
Trial: 12066727
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine solution 3 mg kg(‐1) (n=20)
Trial: 12066727
Drug: mepivacaine 5
RxNorm normalized name: mepivacaine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepivacaine 5 mg kg(‐1) (n=22)
Trial: 12066727
Drug: lidocaine 3
RxNorm normalized name: Lidocaine 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 3 mg kg(‐1) (n=20)
Trial: 8872694
Drug: Oral glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glycopyrrolate
Trial: 31414980
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy with <5 g long chain triglyceride fat per day recommended by dietitians in Australia/New Zealand, UK, and Ireland
Trial: 31414980
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy duration of 4 weeks or 6 weeks
Trial: 28577680
Drug: Udenafil 87.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 87.5 mg bid
Trial: 28577680
Drug: Udenafil (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil (various doses: 37.5, 87.5, 125 mg daily, 37.5 and 87.5 mg bid)
Trial: 24127442
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (no GO)
Trial: 20852004
Drug: Pantoprazole (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (both doses)
Trial: 17006117
Drug: Chlorhexidine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.2% wt/vol oral rinse
Trial: 17006117
Drug: Benzydamine 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine 0.15% wt/vol oral rinse
Trial: 14602795
Drug: Recombinant GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant GH (5 micro g/kg.d)
Trial: 14602795
Drug: GH receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH receptor antagonism
Trial: 2946507
Drug: Isradipine 10
RxNorm normalized name: isradipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 10 mg b.i.d.
Trial: 2946507
Drug: Isradipine 20
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine 20 mg b.i.d.
Trial: 20230914
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones 200mg daily
Trial: 12878791
Drug: Recent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent treatment protocol (surgery, craniospinal irradiation, 4 courses of chemotherapy including VCR, VP, CBDCA, CTX, IF, CDDP, followed by 8 courses of maintenance chemotherapy with VCR, CDDP, CCNU)
Trial: 12878791
Drug: Earlier treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier treatment protocol (surgery and radiotherapy followed by chemotherapy)
Trial: 12878791
Drug: Recent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent treatment protocol for high-risk patients
Trial: 12878791
Drug: Earlier treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier treatment protocol for high-risk patients
Trial: 7875183
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ibopamine (IBO)
Trial: 7875183
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide mononitrate (ISMN)
Trial: 2831248
Drug: Test diet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test diet (1660 mg phosphorus, 420 mg calcium)
Trial: 2831248
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (820 mg calcium, 930 mg phosphorus)
Trial: 19593941
Drug: 1 gram
RxNorm normalized name: guar gum 1 gram ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram of fish oil daily for 6 months (containing 180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid)
Trial: 15136062
Drug: L-arginine (6g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (6g per day)
Trial: 10193230
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch with infiltration analgesia (2 ml lignocaine 2% with adrenaline)
Trial: 26317258
Drug: Continuous local
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous local wound infusion treatment in addition to WHO standard pain management protocol (Group 1)
Trial: 26317258
Drug: Continuous local
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous local wound infusion treatment (Group 1)
Trial: 21398011
Drug: 0.05% tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tranexamic acid in normal saline solution
Trial: 10756406
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CC)
Trial: 7343379
Drug: Metoprolol RETARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol RETARD 100 mg
Trial: 7343379
Drug: Metoprolol RETARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol RETARD 200 mg
Trial: 29892933
Drug: TJ-100 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ-100 (15 g/day)
Trial: 22102633
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg allopurinol (with an interval of 12 h) starting within 4 h after birth
Trial: 20429491
Drug: Antibiotics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics treatment for trichomoniasis (365 women, 83%)
Trial: 20429491
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for trichomoniasis (63 women, 15%)
Trial: 17047001
Drug: TEC (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2) every 3 weeks
Trial: 17047001
Drug: EC‐‐>T (E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐‐>T (E 100 mg/m2, C 600 mg/m2 x 4, then T 100 mg/m2 x 4) every 2 weeks